Tofacitinib in Ulcerative Colitis - Second-Line Therapy, First-Rate Results
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Chen X, Xiang X, Xia W, Li X, Wang S, Ye S
. Evolving Trends and Burden of Inflammatory Bowel Disease in Asia, 1990-2019: A Comprehensive Analysis Based on the Global Burden of Disease Study. J Epidemiol Glob Health. 2023; 13(4):725-739.
PMC: 10686927.
DOI: 10.1007/s44197-023-00145-w.
View
2.
Park S
. Update on the epidemiology of inflammatory bowel disease in Asia: where are we now?. Intest Res. 2022; 20(2):159-164.
PMC: 9081986.
DOI: 10.5217/ir.2021.00115.
View
3.
Vieujean S, Laharie D, Buisson A, Roblin X, Fumery M, Nancey S
. Histological healing induced by tofacitinib in ulcerative colitis: A multicentre study. Dig Liver Dis. 2023; 56(4):613-621.
DOI: 10.1016/j.dld.2023.11.022.
View
4.
Carvalhas Gabrielli A, Ferretti F, Monico C, Tombetti E, Maconi G, Romeo S
. Effect of Tofacitinib on One-Year Colectomy Risk in Anti-TNF Refractory Ulcerative Colitis: A Prospective Multicenter Italian Study. Dig Dis Sci. 2024; 69(5):1785-1792.
DOI: 10.1007/s10620-024-08394-w.
View
5.
Fumery M, Xiaocang C, Dauchet L, Gower-Rousseau C, Peyrin-Biroulet L, Colombel J
. Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies. J Crohns Colitis. 2013; 8(6):469-79.
DOI: 10.1016/j.crohns.2013.09.021.
View